2024
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
Nanda R, Cohen R, Quandt Z, Basu A, Yau C, Chien A, Pusztai L, Han H, Stringer-Reasor E, Isaacs C, Hershman D, Shatsky R, Perlmutter J, Yee D, DeMichele A, van 't Veer L, Hylton N, Esserman L, Rugo H. Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial. Journal Of Clinical Oncology 2024, 42: 584-584. DOI: 10.1200/jco.2024.42.16_suppl.584.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsEarly breast cancerIncidence of AIAdrenal insufficiencyI-SPY2Advanced diseaseBreast cancerRisk of immune-related adverse eventsHigh-risk early breast cancerImmune checkpoint inhibitor doseTriple-negative breast cancerAnti-LAG-3Approval of pembrolizumabEvaluate novel agentsICI-based therapyWeekly x 4Rate of adrenal insufficiencyPhase 2 trialI-SPY2 trialTime to onsetAge of ptsCheckpoint inhibitorsNeoadjuvant settingWeekly paclitaxel
2023
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypes
2012
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research And Treatment 2012, 137: 631-636. PMID: 23242617, PMCID: PMC3867793, DOI: 10.1007/s10549-012-2374-0.Peer-Reviewed Original ResearchConceptsBreast cancerBone metastasesStage IP1NP levelsSerum levelsIL-6Procollagen type I N-terminal propeptideType I N-terminal propeptideCox proportional hazards regression analysisProportional hazards regression analysisEarly-stage breast cancerPoor OS rateSerum P1NP levelsKaplan-Meier methodOverall survival rateHazards regression analysisLower overall survivalBone metastasis developmentBreast cancer metastasisBlood sample collectionN-terminal propeptideAdvanced diseaseOverall survivalOS ratesSerum P1NPEvaluation of circulating biomarkers of bone metastases in early-stage breast cancer.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10-10. DOI: 10.1200/jco.2012.30.30_suppl.10.Peer-Reviewed Original ResearchP1NP levelsBreast cancerStage IInterleukin-6Cox proportional hazards regression analysisStage IV breast cancerElecsys 2010Proportional hazards regression analysisKaplan-Meier methodTime of diagnosisHazards regression analysisWorse overall survivalBone metastasis developmentProcollagen type 1Breast cancer recurrenceRoche Elecsys 2010Advanced diseaseMetastatic diseaseOverall survivalBone metastasesClinical factorsSerum levelsSerum P1NPBone turnoverBiomarker levelsEvaluation of circulating biomarkers of bone metastasis in early-stage breast cancer.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10613-10613. DOI: 10.1200/jco.2012.30.15_suppl.10613.Peer-Reviewed Original ResearchP1NP valuesInterleukin-6Breast cancerClinical factorsHazard ratioCox proportional hazards regression analysisCox proportional hazards regression modelElecsys 2010Proportional hazards regression analysisEarly-stage breast cancerProportional hazards regression modelsSerum P1NP levelsKaplan-Meier methodHazards regression analysisBone metastasis developmentHazards regression modelsProcollagen type 1Breast cancer recurrenceRoche Elecsys 2010Advanced diseaseP1NP levelsBone metastasesSerum levelsBone turnoverUnivariate analysis
2003
HER-2/neu testing in breast cancer.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of Clinical Pathology 2003, 120 Suppl: s53-71. PMID: 15298144, DOI: 10.1309/949fpq1aq3p0rlc0.Peer-Reviewed Original ResearchConceptsBreast cancerNeu testingNeu statusProspective clinical outcome studyTrastuzumab-based therapyMajor clinical trialsEarly clinical stagePredictors of responseClinical outcome studiesBreast cancer specimensAdvanced diseaseClinical responseClinical stageClinical trialsStandards of practiceCancer specimensImmunohistochemical analysisOutcome studiesPotential efficacyCancerSitu hybridization techniqueRecent evidenceTherapySitu hybridization methodExcellent results
1998
Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model
Pusztai L, Siddik Z, Mills G, Bast R. Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model. Acta Oncologica 1998, 37: 629-640. PMID: 10050979, DOI: 10.1080/028418698429964.Peer-Reviewed Original ResearchConceptsEarly-stage ovarian cancerDrug-resistant cellsDrug resistanceDrug sensitivityOvarian cancerTumor progressionDisease-free survivalHigh-dose chemotherapyNumerous clinical studiesDifferent treatment strategiesCell populationsHigh response rateCorresponding normal tissuesInsufficient chemotherapyAdjuvant chemotherapyIntensive chemotherapyAdvanced diseaseClinical responseCombination chemotherapyConventional dosesMolecular biological observationsOvarian carcinomaPhysiological drug resistanceClinical failureClinical studies